ImmunityBio IBRX enters the post-earnings stretch with the stock at $7.72 (as of May 28, 2026) and a six to12 month price target of $8.25. After a 289.9% year-to-date surge, the setup is less about “what’s next” and more about what has already been priced in.
The base case is an in-line performance profile tied to Anktiva’s commercial trajectory, with near-term upside requiring continued proof that demand is still accelerating after the run.
IBRX Stock Snapshot and What It Implies
IBRX has already delivered a sharp rerating, and the valuation reflects it. The shares are trading at 23.41x forward twelve-month sales versus 1.96x for the Zacks sub-industry, 2.12x for the Zacks sector and 5.25x for the S&P 500. That gap raises the bar for execution, especially for a company whose revenue base is still concentrated in a single marketed product.
Against that backdrop, the $8.25 six to 12 month price target implies a more measured path from here. For investors, the practical question is whether the next few quarters extend the current adoption trend enough to justify what the market is already discounting after the stock’s outsized move.
ImmunityBio’s Q1 Print Is Mixed, Not Broken
First-quarter 2026 results landed as a modest earnings miss with a revenue beat. ImmunityBio posted an adjusted loss of 9 cents per share versus the consensus loss of 8 cents, while revenue came in at $44.2 million versus $41.1 million.
The adjusted figure excluded a large one-time fair-value change tied to warrant and derivative liabilities as well as the related-party convertible note. Including that line item, loss per share was 62 cents, compared with 15 cents a year ago. In other words, the quarter was not clean, but the core takeaway stayed centered on whether Anktiva’s commercial ramp remains intact.
IBRX Demand Signals: New Prescribers and Repeat Ordering
The quarter reinforced a demand narrative that is increasingly about breadth, not just initial uptake. Management pointed to strong demand from new prescribers and broader use across eligible patients, including in the maintenance setting.
That matters because repeat ordering is the clearest sign that early trial use is translating into routine practice. Management framed repeat ordering as a driver of continued momentum, supporting quarter-over-quarter growth since launch.
ImmunityBio, Inc. Price
ImmunityBio, Inc. price | ImmunityBio, Inc. Quote
ImmunityBio Expenses Rise as It Scales the Launch
The commercial build is showing up in operating expenses. Research and development expense rose to $68 million from $48.2 million a year earlier, driven by higher clinical study costs, headcount-related expenses, consulting fees and external manufacturing costs.
Selling, general and administrative expense increased to $45.8 million from $32.7 million, reflecting higher professional services and headcount-related costs, plus incremental commercial spending and other items tied to scaling operations. The investment cadence underscores an “earnings later” posture that puts even more weight on sustaining the top-line trajectory.
IBRX Near-Term Risk: Ex-U.S. Ramp Can Be Slow
International expansion broadens the long-term opportunity, but the near-term math can be slow. Europe still requires country-by-country reimbursement, with the Big 5 prioritized and Germany expected to commercialize first in 2026. That implies a ramp that may extend into 2027, keeping near-term results disproportionately dependent on the U.S. trajectory.
The company has made progress in securing authorizations across multiple jurisdictions, and commercial availability in Saudi Arabia was achieved quickly after announcing Middle East partnerships. Still, stepwise timing and access decisions can vary by country, and reimbursement friction can delay demand conversion even after regulatory wins.
ImmunityBio Balance Sheet and Complexity Checks
ImmunityBio ended March 2026 with nearly $381 million in cash, cash equivalents and marketable securities, alongside approximately $678 million in total debt (long-term only). The balance sheet also includes sizable fair-value liabilities, including a related-party convertible note valued at $678 million and a $404 million revenue interest liability.
Management provides no margin or EPS guidance, which increases the importance of execution and adoption timing. Regulatory and compliance items can also be a distraction: the company received FDA promotional correspondence and implemented enhanced review protocols.
How To Map a Practical “Hold vs. Add” Decision on IBRX
A workable “hold vs. add” framework starts with what would validate the bullish path. First, investors should look for continued U.S. net product revenues acceleration beyond the 168% year over year and 15% sequential growth rate posted in the first quarter. Second, steady progress converting ex-U.S. authorizations into real demand would help reduce the company’s dependence on a single geography, even if the ramp remains gradual. Third, clean regulatory progress in bladder cancer matters, with the FDA reviewing a filing for Anktiva plus BCG in BCG-unresponsive papillary-only disease and a final decision expected by Jan. 6, 2027, while a BCG-naïve CIS program is positioned for an sBLA submission in 2026.
The bear case is easier to define because it ties directly to timing risk. Slower launches or reimbursement delays in Europe could extend U.S. dependence longer than investors expect. Adoption disappointments would be harder to absorb given the elevated sales multiple. And regulatory or legal distractions, including promotional correspondence, could divert attention during a scaling phase.
In the near term, a Zacks Rank #3 (Hold) aligns with a wait-for-confirmation posture. Industry peers such as Agenus AGEN and Iovance Biotherapeutics IOVA also carry a Zacks Rank #3, reinforcing that this pocket of biotech remains selective and execution-driven rather than broadly risk-on.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN): Free Stock Analysis Report
Iovance Biotherapeutics, Inc. (IOVA): Free Stock Analysis Report
ImmunityBio, Inc. (IBRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).